Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Climb Bio

Climb Bio

Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody medicines for immune-mediated diseases.

: Public company
: 2018
: Wellesley Hills, MA, USUnited States

Climb Bio, Inc. is the current corporate name of the biotechnology company formerly called Eliem Therapeutics, Inc. The rebrand accompanied a refocusing of the company's pipeline on immune-mediated diseases.

Its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells and directly reduce pathogenic autoantibodies. The candidate targets B-cell mediated diseases including systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy, where reducing autoantibodies has the potential to be disease-modifying.

Similar Companies

Ironshore Pharmaceuticals

Tizona Therapeutics

BioClonetics Immunotherapeutics

Upstream Bio

upstreambio.com

IGM Biosciences

igmbio.com

HI-Bio

hibio.com

Basecamp Bio

elevate.bio

TrueBinding

truebinding.com

Oblenio Bio

obleniobio.com

Abcuro

abcuro.com

Clarametyx Biosciences

clarametyx.com

Equillium

equilliumbio.com

Cleveland BioLabs

Opsidio

opsidio.com

Abwiz Bio

abwizbio.com

iBio

ibioinc.com

Infinimmune

infinimmune.com

Imel Biotherapeutics

imelbiotx.com

ImmuneID

Torl Biotherapeutics

torlbio.com

Bolt Biotherapeutics

boltbio.com

Quick Facts

Who are Climb Bio's competitors?

Companies similar to Climb Bio include Tizona Therapeutics, BioClonetics Immunotherapeutics, Upstream Bio and IGM Biosciences.

When was Climb Bio founded?

Climb Bio was founded in 2018.

Where is Climb Bio's headquarters located?

Climb Bio's headquarters is located in Wellesley Hills, MA, US.

When was Climb Bio's last funding round?

Climb Bio's most recent funding round was for $110M (USD) in April 2026.

How much disclosed funding has Climb Bio raised?

As of Apr 28, 2026, Climb Bio has disclosed funding of $110M (USD). Undisclosed round amounts are excluded.

Classification

Industry: Biotechnology
Ownership: Public
Technology: Monoclonal Antibody
Geographic Exposure: United States

Headquarters: 20 William Street
Suite G50
Wellesley Hills, MA, 02481
US

SEC CIK: 0001768446
EIN: 83-2273741